127 related articles for article (PubMed ID: 1605286)
1. The efficacy and tolerability of norgestimate/ethinyl estradiol (250 micrograms of norgestimate/35 micrograms of ethinyl estradiol): results of an open, multicenter study of 59,701 women.
Runnebaum B; Grunwald K; Rabe T
Am J Obstet Gynecol; 1992 Jun; 166(6 Pt 2):1963-8. PubMed ID: 1605286
[TBL] [Abstract][Full Text] [Related]
2. Clinical experience with a new norgestimate-containing oral contraceptive.
Huber J
Int J Fertil; 1991; 36 Suppl 1():25-31. PubMed ID: 1678378
[TBL] [Abstract][Full Text] [Related]
3. Clinical experience with a new norgestimate-containing oral contraceptive.
Huber J
Int J Fertil; 1992; 37 Suppl 1():47-53. PubMed ID: 1347520
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris.
Lucky AW; Henderson TA; Olson WH; Robisch DM; Lebwohl M; Swinyer LJ
J Am Acad Dermatol; 1997 Nov; 37(5 Pt 1):746-54. PubMed ID: 9366821
[TBL] [Abstract][Full Text] [Related]
5. Cycle control with triphasic norgestimate and ethinyl estradiol, a new oral contraceptive agent.
Andolsek KM
Acta Obstet Gynecol Scand Suppl; 1992; 156():22-6. PubMed ID: 1324553
[TBL] [Abstract][Full Text] [Related]
6. Clinical evaluation of a new triphasic oral contraceptive: norgestimate and ethinyl estradiol.
Gauthier A; Upmalis D; Dain MP
Acta Obstet Gynecol Scand Suppl; 1992; 156():27-32. PubMed ID: 1324554
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of a monophasic and a triphasic oral contraceptive containing norgestimate.
Corson SL
Am J Obstet Gynecol; 1994 May; 170(5 Pt 2):1556-61. PubMed ID: 8178906
[TBL] [Abstract][Full Text] [Related]
8. Long-term profile of a new progestin.
Lippman J
Int J Fertil; 1992; 37 Suppl 4():218-22. PubMed ID: 1362189
[TBL] [Abstract][Full Text] [Related]
9. [Clinical study of a triphasic contraceptive preparation (Norgestimate 180/215/250 micrograms + ethinylestradiol 35 micrograms) in a population of Czech women].
Paseka J; Unzeitig V; Horejsí J; Rotta L; Chroust K; Cibula D
Ceska Gynekol; 1999 Jul; 64(4):246-54. PubMed ID: 10568064
[TBL] [Abstract][Full Text] [Related]
10. Comparison of a novel norgestimate/ethinyl estradiol oral contraceptive (Ortho Tri-Cyclen Lo) with the oral contraceptive Loestrin Fe 1/20.
Hampton RM; Short M; Bieber E; Bouchard C; Ayotte N; Shangold G; Fisher AC; Creasy GW
Contraception; 2001 Jun; 63(6):289-95. PubMed ID: 11672549
[TBL] [Abstract][Full Text] [Related]
11. A norgestimate-containing oral contraceptive: review of clinical studies.
Kafrissen ME
Am J Obstet Gynecol; 1992 Oct; 167(4 Pt 2):1196-202. PubMed ID: 1415446
[TBL] [Abstract][Full Text] [Related]
12. Norgestimate: a clinical overview of a new progestin.
Bringer J
Am J Obstet Gynecol; 1992 Jun; 166(6 Pt 2):1969-77. PubMed ID: 1605287
[TBL] [Abstract][Full Text] [Related]
13. Cycle control, tolerability, and satisfaction among women switching from 30-35 microg ethinyl estradiol-containing oral contraceptives to the triphasic norgestimate/25 microg ethinyl estradiol-containing oral contraceptive Ortho Tri-Cyclen LO.
Poindexter AN; Burkman R; Fisher AC; LaGuardia KD
Int J Fertil Womens Med; 2003; 48(4):163-72. PubMed ID: 13677549
[TBL] [Abstract][Full Text] [Related]
14. A multicenter clinical investigation employing ethinyl estradiol combined with dl-norgestrel as postcoital contraceptive agent.
Yuzpe AA; Smith RP; Rademaker AW
Fertil Steril; 1982 Apr; 37(4):508-13. PubMed ID: 7040117
[TBL] [Abstract][Full Text] [Related]
15. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.
Teichmann A
Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():98-104. PubMed ID: 8574257
[TBL] [Abstract][Full Text] [Related]
16. Experience with a new low dose oral contraceptive: norgestimate & ethinyl estradiol.
Rubio-Lotvin B; Gonzales-Ansorena R
Acta Eur Fertil; 1978 Mar; 9(1):1-6. PubMed ID: 696184
[TBL] [Abstract][Full Text] [Related]
17. Metabolic effects and efficacy of a triphasic oral contraceptive (norgestimate/ethinyl estradiol).
Andolsek KM; Burkman RT; Kafrissen ME; Olson W; Osterman J
Int J Fertil Menopausal Stud; 1993; 38 Suppl 3():122-5. PubMed ID: 8260970
[No Abstract] [Full Text] [Related]
18. Influence of alitretinoin on the pharmacokinetics of the oral contraceptive ethinyl estradiol/norgestimate.
Schmitt-Hoffmann AH; Roos B; Sauer J; Schleimer M; Schoetzau A; Leese PT; Weidekamm E; Maares J
Clin Exp Dermatol; 2011 Apr; 36 Suppl 2():4-11. PubMed ID: 21443598
[TBL] [Abstract][Full Text] [Related]
19. Effect of the coadministration of daclatasvir on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate.
Bifano M; Sevinsky H; Hwang C; Kandoussi H; Jiang H; Grasela D; Bertz R
Antivir Ther; 2014; 19(5):511-9. PubMed ID: 24343001
[TBL] [Abstract][Full Text] [Related]
20. Five-year, multicenter study of a triphasic, low-dose, combination oral contraceptive.
Woutersz TB; Korba VD
Int J Fertil; 1988; 33(6):406-10. PubMed ID: 2906915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
